BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Biotechnology

Healthcare
$1.81 -0.39%

-$0.03 today

Market cap
$144.85M
Beta
0.29
P/E (TTM)
-1.5
EPS (TTM)
-$4.95
52W Low $7.00High $14.87

Volume 0.58M

Average 0.37M

BBOT Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Income Tax Expense vs competitors

How BBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
BBOT Competitors
Income Tax Expense for BBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$13.34M USD+1636.3%—1.9%
XNCRXencor, Inc.LTM Jun 2026$2.48M USD+53.2%+55.0%2.4%
ANABAnaptysBio, Inc.LTM Mar 2026$160K USD+240.4%+89.8%0.1%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$0 USD———
KODKodiak Sciences Inc.LTM Sep 2026$0 USD———
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
TNGXTango Therapeutics, Inc.LTM Sep 2026-$53K USD-149.1%-58.0%—
OCSOculis Holding AGLTM Mar 2026-CHF 291.8K CHF-59.5%+47.8%57.9%
SEPNSepterna, Inc.LTM Sep 2026-$3.3M USD-1961.9%—3.4%
URGNUroGen Pharma Ltd.LTM Mar 2026-$5.09M USD-260.4%-64.6%3.6%
Peer median (excluding BBOT) —-59.5%+47.8%2.4%

Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development0056.29M73.11M121.2M
Selling, General & Admin43.36K3.52K8.49M7.76M24.62M
Operating Expenses43.36K3.52K64.77M80.86M145.82M
Depreciation & Amortization74.33K3.52K92K208K610K
EBITDA(43.36K)(3.52K)(64.68M)(80.66M)(145.21M)
EBITDA Margin—————
Operating Income(43.36K)(3.52K)(64.77M)(80.86M)(145.82M)
Operating Margin—————
Interest Income0072K8.46M11.34M
Interest Expense00000
Other Income / Expenses0072K8.18M11.78M
Income Before Tax(43.36K)(3.52K)(64.7M)(74.28M)(134.04M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.36K)(3.52K)(64.7M)(74.28M)(134.04M)
Net Margin—————
EPS (Basic)(0.00)0.00(3.16)0.46(4.30)
EPS (Diluted)(0.00)(0.00)(3.16)0.46(4.30)
Weighted Avg Shares20.49M20.49M20.49M16.64M31.14M
Weighted Avg Shares (Diluted)20.49M20.49M20.49M16.64M31.14M

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

Intrinsic Alpha fair value

Locked

Current Price

$1.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.